Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of CFT8919 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study of CFT8919 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CFT 8919 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors C4 Therapeutics

    • Most Recent Events

    • 05 Jul 2023 According to a C4 Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CFT8919.
    • 09 Jan 2023 According to a C4 Therapeutics media release, the company anticipates to submit an IND application in the first half of 2023.
    • 05 May 2022 According to a C4 Therapeutics media release, company anticipate to complete IND-enabling activities for CFT8919 by year-end 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top